$MDXG (MiMedx Group, Inc.)

$MDXG {{ '2016-07-08T18:50:33+0000' | timeago}} • Announcement

$MDXG said that Dr. I. Mark Landy has joined as the company's VP responsible for key strategic initiatives. In his new role, Mark will support certain domestic and international strategic imperatives and related growth initiatives. Mark will report to Chairman and CEO Parker H. Petit.

$MDXG {{ '2017-09-19T15:22:20+0000' | timeago}} • Announcement

$MDXG has filed with the FDA to initiate its Investigational New Drug (IND) Phase 2 clinical trial for osteoarthritis of the knee. The objective is to determine the safety and effectiveness of AmnioFix Injectable as compared to the 0.9% Sodium Chloride USP placebo injection control for the treatment of knee osteoarthritic pain.

$MDXG {{ '2017-09-13T13:59:54+0000' | timeago}} • Announcement

$MDXG said its production operations in Georgia and placenta recovery functions are operating normally, and its previously published expectation for 3Q17 revenue to exceed the $80MM mark is unaffected by Hurricane Irma. $MDXG remains confident in its ability to meet or exceed revenue projections for 2017, which are at $309-311MM range.

$MDXG {{ '2017-09-07T14:14:35+0000' | timeago}} • Announcement

$MDXG said it received green signal from the FDA to proceed with a new drug phase-3 clinical study of its AmnioFix injection, for the treatment of Achilles Tendonitis. MiMedx expects to commence patient enrollment in the next quarter. The objective of the study is to determine the safety and effectiveness of the formulation, compared to placebo.

$MDXG {{ '2017-09-05T17:12:01+0000' | timeago}} • Announcement

Biopharmaceutical company $MDXG said that its expectation for 3Q17 revenue is expected to exceed $80MM, the high end of its 3Q17 revenue guidance range. The company previously guided to a 3Q17 revenue range of $79-80MM. The updated guidance is based on the strength of its July and August revenue performance.

$MDXG {{ '2017-08-31T13:03:59+0000' | timeago}} • Announcement

Pharma firm $MDXG said its latest peer-reviewed study of MiMedx dehydrated human amnion/chorion membrane (EpiFix) allografts was accepted for publication in the International Wound Journal. Patients treated with EpiFix showed VLU healing rates of 60% within 12 weeks and 71% within 16 weeks - a superior healing rate compared to the other studies.

$MDXG {{ '2017-08-18T19:33:28+0000' | timeago}} • Announcement

$MDXG will divest its Stability Biologics subsidiary as part of its strategic focus on biopharma. The company expects to book a one-time gain on this transaction of approx. $8-10MM. If the deal closes in 3Q17, $MDXG will maintain its FY17 revenue guidance of $309-311MM. $MDXG is reaffirming all guidance ranges for 3Q17 and FY17.

$MDXG {{ '2017-08-18T19:32:40+0000' | timeago}} • Announcement

$MDXG agreed to divest its Stability Biologics LLC subsidiary to the former stockholders of Stability Inc. The deal is expected to close in 3Q17. The consideration will include a promissory note issued by Stability Biologics for $3.5MM in favor of $MDXG and a waiver by the former Stability stockholders of all claims to the earn-out consideration.

$MDXG {{ '2017-08-17T16:40:41+0000' | timeago}} • Announcement

$MDXG provided update on litigation with terminated employees. These civil cases are proceeding at a rapid pace toward trial and/or settlement. However, certain terminated employees are continuing their attempts to publicly defame the company through misinformation, which has resulted in tortious interference civil actions.

$MDXG {{ '2017-08-17T16:35:51+0000' | timeago}} • Announcement

$MDXG provided an update on its litigation with certain former employees. The company filed lawsuits against certain former employees on Dec. 13, 2016 for, among other things, selling competing products while full-time employees of $MDXG. The company is also seeking monetary damages in an amount to be determined at trial.

$MDXG {{ '2017-08-04T21:07:25+0000' | timeago}} • Announcement

$MDXG filed with the FDA to initiate its Investigational New Drug (IND) Phase 3 Achilles Tendonitis clinical study. The trial will study $MDXG’s AmnioFix Injectable in a Phase 3 randomized controlled trial of the micronized dHACM Injection as compared to saline placebo injection in the treatment of Achilles Tendonitis.

$MDXG {{ '2017-04-28T18:56:53+0000' | timeago}} • Announcement

$MDXG sees 2Q17 revenue at $73.5-75MM, pushing the FY17 revenue guidance to $303.5-307MM. Gross profit margins for the year is expected to be 86-88%, with operating earnings growing by 90% or greater. MiMedx estimates GAAP EPS to be $0.18-0.20, with net earnings rising over 95% for FY17.

$MDXG {{ '2017-04-28T18:52:27+0000' | timeago}} • Announcement

$MDXG's revenue soared 36% to $72.6MM in 1Q17, as biopharma product maker's net income more than tripled to $4.3MM from last year's $1.2MM. Earnings jumped to $0.04 per diluted share from last year's $0.01 a share, helped by revenues from Wound Care segment rising 40% and SSO segment growing by 26%.

$MDXG {{ '2017-03-20T12:16:26+0000' | timeago}} • Announcement

$MDXG's BoD appointed Luis Aguilar, former Commissioner of the U.S. Securities and Exchange Commission (SEC) and highly accomplished lawyer within industry and private law practice, as an independent, non-employee Director. Aguilar will be nominated as a Class I Director to serve for a 3-year term expiring at the 2020 Annual Meeting.

$MDXG {{ '2017-02-06T13:00:38+0000' | timeago}} • Announcement

$MDXG BoD authorized an increase in the company's share repurchase program of $10MM, bringing the total authorization to $76MM since the share repurchase program commenced in May 2014.

$MDXG {{ '2017-01-10T16:05:43+0000' | timeago}} • Announcement

$MDXG posted revenue of $71.6MM for 4Q16, which was in the upper range of guidance and represents a growth of 38% over 4Q15. For 1Q17, revenue is expected to be $69.5-72.5MM. For FY17, $MDXG expects revenue of $302-307MM and GAAP EPS of $0.18-0.20. 2017 GAAP net earnings is expected to grow in excess of 95%.

$MDXG {{ '2016-10-10T17:57:51+0000' | timeago}} • Announcement

$MDXG reported a 31% jump in 3Q16 revenue driven by strong growth in the commercial side of its wound care business, despite vacations impact. Revenue grew to $64.4MM from $49MM last year. With many year-end deductibles being met during 4Q16, $MDXG expects typical additive impact on 4Q revenue. $MDXG plans to release 3Q results on Oct. 27, 2016.

$MDXG {{ '2016-08-31T12:19:46+0000' | timeago}} • Announcement

$MDXG said it provided an update on the status of key clinical trials. $MDXG said plantar fasciitis Investigational New Drug study received FDA approval for protocol amendment reducing follow-up requirements by one year.

$MDXG {{ '2016-07-12T14:07:46+0000' | timeago}} • Announcement

$MDXG recorded revenue for 2Q16 of $57.3MM, an 26% increase over 2Q15 revenue of $45.7MM. For 1H16, the company recorded revenue of $110.7MM, a 28% increase over revenue of $86.4MM recorded in the same period of 2015. CEO Parker Petit said the company gained significant positive momentum during 2Q16 and believes it should continue throughout year.

$MDXG {{ '2016-07-08T18:50:33+0000' | timeago}} • Announcement

$MDXG said that Dr. I. Mark Landy has joined as the company's VP responsible for key strategic initiatives. In his new role, Mark will support certain domestic and international strategic imperatives and related growth initiatives. Mark will report to Chairman and CEO Parker H. Petit.

$MDXG {{ '2016-06-27T14:49:00+0000' | timeago}} • Announcement

$MDXG said it has agreed to terms of settlement with each of Medline Industries and Liventa Bioscience for false advertising claims asserted against each of them by $MDXG. In April 2014, $MDXG filed a lawsuit in Northern District Court of Georgia against Musculoskeletal Transplant Foundation, Medline, and Liventa for permanent injunctive relief.

Recent Transcripts

NEOG (Neogen Corp.)
Tuesday, September 19 2017 - 3:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, August 3 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, August 2 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, August 2 2017 - 8:30pm
CAH (Cardinal Health, Inc.)
Wednesday, August 2 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
RMD (ResMed Inc.)
Tuesday, August 1 2017 - 8:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
MDXG (MiMedx Group, Inc.)
Thursday, July 27 2017 - 2:30pm
ZBH (Zimmer Biomet Holdings, Inc.)
Thursday, July 27 2017 - 12:00pm
SNN (Smith & Nephew plc)
Thursday, July 27 2017 - 8:00am
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
VAR (Varian Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
UHS (Universal Health Services Inc.)
Wednesday, July 26 2017 - 1:00pm

AlphaGraphics you may like